Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Rani Therapeutics Holdings, Inc.

Get SEC filing alerts via email and in your feed for Rani Therapeutics Holdings, Inc.

RANI

Rani Therapeutics Holdings, Inc.

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics develops oral biotherapeutic delivery platforms, primarily the RaniPill capsule, to administer biologics such as antibodies, peptides, and proteins. Its technology aims to replace injections with convenient oral dosing, targeting markets like obesity, inflammatory diseases, and osteoporosis. The company collaborates with biopharma partners, advancing a pipeline of clinical and preclinical biologic candidates with high bioavailability and precision delivery.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Rani Therapeutics Holdings, Inc.

1
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports $1.7M Revenue in Q1 2026, Significant Year-Over-Year Growth

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports $41M Net Loss, Increases Cash Reserves and Enters Collaboration with Chugai

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports Decreased Net Losses and Strategic Collaborations in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports $11.2 Million Net Loss in Q2 2025, Sees Decrease in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports $12.7 Million Net Loss and First Revenue Recognition

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports $56.6M Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Rani Therapeutics Holdings, Inc. Rani Therapeutics Reports 33.9% Decrease in Operating Expenses, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments